Edition:
United States

OraSure Technologies Inc (OSUR.O)

OSUR.O on Nasdaq

8.61USD
19 Jan 2017
Change (% chg)

$-0.12 (-1.37%)
Prev Close
$8.73
Open
$8.78
Day's High
$8.78
Day's Low
$8.50
Volume
292,426
Avg. Vol
500,883
52-wk High
$9.53
52-wk Low
$5.09

Latest Key Developments (Source: Significant Developments)

Orasure Technologies appoints Stephen Tang as chairman of the board of directors
Tuesday, 15 Nov 2016 06:00am EST 

Orasure Technologies Inc : Orasure Technologies Inc- appointment of Stephen S. Tang, as chairman of company's board of directors effective November 14, 2016 . Orasure Technologies Inc- retirement of Douglas G. Watson as a director and chairman of board, effective November 13, 2016 .Orasure Technologies appoints Stephen S. Tang, PH.D. As chairman of the board of directors.  Full Article

Orasure awarded up to $16.6 mln to advance rapid zika tests
Tuesday, 23 Aug 2016 04:00pm EDT 

Orasure Technologies Inc : Awarded up to $16.6 million to advance rapid zika tests . Six-year, multi-phased contract includes an initial commitment of $7.0 million .Contract includes options for upto additional $9.6 million to fund evaluation of additional product enhancements,regulatory activities.  Full Article

Orasure Technologies reports earnings per share of $0.07
Wednesday, 3 Aug 2016 04:00pm EDT 

Orasure Technologies Inc : Orasure announces 2016 second quarter financial results . Q2 earnings per share $0.07 . Q2 revenue $31.4 million versus I/B/E/S view $31.2 million . Q2 earnings per share view $0.05 -- Thomson Reuters I/B/E/S . Sees Q3 2016 earnings per share $0.07 to $0.08 . Orasure Technologies Inc sees consolidated net income for Q3 between $0.07 and $0.08 per share . Orasure Technologies Inc says company expects consolidated net revenues for Q3 to range from $31.25 million to $31.75 million .Q3 earnings per share view $0.08, revenue view $34.6 million -- Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc gives Q4 2015 mixed guidance
Wednesday, 4 Nov 2015 04:00pm EST 

OraSure Technologies Inc:Expects Q4 2015 consolidated net revenues to range from $29.5 to $30.0 million and is projecting a consolidated net income of between $0.03 and $0.04 per share.Q4 2015 revenue of $31 million and EPS of $0.01 - Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc provides update on oraquick ebola rapid antigen test business
Tuesday, 29 Sep 2015 06:00am EDT 

OraSure Technologies Inc:Provides update on oraquick ebola rapid antigen test business.Says made progress regarding the commercialization of its oraquick ebola rapid antigen test.Says Hhs' centers for disease control and prevention will purchase about $1.5 million of the company's oraquick ebola rapid antigen test.Cdc purchase is expected to be fulfilled by the end of 2015.Cdc is purchasing the oraquick ebola rapid antigen tests for field testing in west Africa.U.S. department of health and human services to provide $7.2 million in additional funding for co's oraquick ebola rapid antigen test.Funding will be used for clinical and regulatory activities required to request FDA 510(k) clearance for product.  Full Article

OraSure Technologies Inc gives Q3 2015 guidance; revenue guidance above analysts' estimates
Wednesday, 5 Aug 2015 04:14pm EDT 

OraSure Technologies Inc:Expects Q3 2015 consolidated net revenues to range from $29.5 to $30.0 million and is projecting a consolidated bottom line performance of breakeven to a consolidated net loss of ($0.01) per share.Q3 2015 revenue of $29.3 million and EPS of $0.00 - Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc received FDA emergency use authorization for ebola diagnostic test
Monday, 3 Aug 2015 06:00am EDT 

OraSure Technologies Inc:Receives FDA emergency use authorization for ebola rapid diagnostic test.Says test has not been cleared or approved by FDA.Test authorized by FDA under EUA for use by laboratories,facilities adequately equipped, trained, capable of testing for ebola.Received U.S. FDA emergency use authorization for oraquick ebola rapid antigen test for use with fingerstick, venous whole blood.  Full Article

OraSure awarded $10.4 million HHS contract to advance Rapid Ebola Test Clinical Development
Friday, 12 Jun 2015 07:30am EDT 

OraSure Technologies Inc:Has been awarded contract for up to $10.4 mln in total funding from the U.S. Department of Health and Human Services (HHS) Office of Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority related to the Company's OraQuick Ebola Rapid Antigen Test.The three-year, multi-phased contract includes an initial commitment of $1.8 mln and options for up to an additional $8.6 mln to fund certain clinical and regulatory activities.  Full Article

OraSure Technologies Inc gives Q2 2015 guidance in line with analysts' estimates
Wednesday, 6 May 2015 04:00pm EDT 

OraSure Technologies Inc:Expects Q2 2015 consolidated net revenues to range from $29.0 to $29.5 million.Expects Q2 2015 consolidated net income of about $0.00 to $0.01 per share.Q2 2015 revenue of $29.2 million and EPS of $0.00 - Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc gives Q1 2015 EPS guidance above analysts' estimates; revenue guidance below analysts' estimates
Wednesday, 4 Feb 2015 04:00pm EST 

OraSure Technologies Inc:Expects Q1 2015 consolidated net revenues to range from $26.5 to $27.0 million.Q1 2015 consolidated net loss of about $0.01 to $0.02 per share.Q1 2015 revenue of $27.3 million and EPS of $(0.03) - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Orasure Technologies appoints Stephen Tang as chairman of the board of directors

* Orasure Technologies Inc- appointment of Stephen S. Tang, as chairman of company's board of directors effective November 14, 2016